Immune Checkpoint Inhibitors for Unresectable Hepatocellular Carcinoma.
CPI
HCC
immunotherapy
progression
survival
Journal
Vaccines
ISSN: 2076-393X
Titre abrégé: Vaccines (Basel)
Pays: Switzerland
ID NLM: 101629355
Informations de publication
Date de publication:
19 Oct 2020
19 Oct 2020
Historique:
received:
14
09
2020
revised:
06
10
2020
accepted:
14
10
2020
entrez:
22
10
2020
pubmed:
23
10
2020
medline:
23
10
2020
Statut:
epublish
Résumé
Despite the advances in screening protocols and treatment options, hepatocellular carcinoma (HCC) is still considered to be the most lethal malignancy in patients with liver cirrhosis. Moreover, the survival outcomes after failure of first-line therapy for unresectable HCC is still poor with limited therapeutic options. One of these options is immune checkpoint inhibitors. The aim of this study is to comprehensively review the efficacy and safety of immune checkpoint inhibitors for patients with HCC.
Identifiants
pubmed: 33086471
pii: vaccines8040616
doi: 10.3390/vaccines8040616
pmc: PMC7712941
pii:
doi:
Types de publication
Journal Article
Review
Langues
eng
Références
Liver Cancer. 2016 Nov;6(1):16-26
pubmed: 27995084
Liver Cancer. 2019 Feb;8(1):1-11
pubmed: 30815391
Science. 2008 Oct 10;322(5899):271-5
pubmed: 18845758
Immunol Rev. 2010 Jul;236:219-42
pubmed: 20636820
J Clin Oncol. 2014 Apr 20;32(12):1210-7
pubmed: 24637999
Oncogene. 2020 Apr;39(18):3620-3637
pubmed: 32157213
Ann Oncol. 2017 Jul 1;28(suppl_4):iv119-iv142
pubmed: 28881921
J Clin Oncol. 2018 Jul 1;36(19):1905-1912
pubmed: 29746230
N Engl J Med. 2008 Jul 24;359(4):378-90
pubmed: 18650514
Cancer Lett. 2013 Oct 28;340(1):97-103
pubmed: 23856031
Nat Rev Clin Oncol. 2018 May;15(5):325-340
pubmed: 29508855
Lancet Oncol. 2019 Feb;20(2):282-296
pubmed: 30665869
Aliment Pharmacol Ther. 2018 Sep;48(6):598-609
pubmed: 30039640
Mol Cancer Ther. 2008 Oct;7(10):3129-40
pubmed: 18852116
Front Immunol. 2018 May 30;9:1125
pubmed: 29910803
Clin Cancer Res. 2009 Feb 1;15(3):971-9
pubmed: 19188168
J Immunother Cancer. 2018 Sep 25;6(1):95
pubmed: 30253811
Cell. 2011 Mar 4;144(5):646-74
pubmed: 21376230
Front Mol Neurosci. 2020 Aug 14;13:156
pubmed: 32922263
Hepatol Commun. 2020 Jun 16;4(7):1073-1086
pubmed: 32626838
N Engl J Med. 2004 Jun 3;350(23):2335-42
pubmed: 15175435
Int J Cancer. 2011 Feb 15;128(4):887-96
pubmed: 20473887
Lancet. 2017 Jun 24;389(10088):2492-2502
pubmed: 28434648
Oncotarget. 2017 Feb 7;8(6):10703-10713
pubmed: 27793044
Lancet Oncol. 2018 Jul;19(7):940-952
pubmed: 29875066
Cancers (Basel). 2020 Apr 03;12(4):
pubmed: 32260179
Clin Liver Dis (Hoboken). 2013 Jan 23;1(6):180-182
pubmed: 31186882
J Hepatol. 2017 Mar;66(3):545-551
pubmed: 27816492
Nat Rev Clin Oncol. 2016 Aug;13(8):473-86
pubmed: 27141885
Int J Cancer. 2008 Feb 1;122(3):664-71
pubmed: 17943726
Eur J Cancer. 2018 Mar;91:21-29
pubmed: 29331748
Hepatology. 2019 Mar;69(3):1064-1074
pubmed: 30014489
Nat Genet. 2014 Dec;46(12):1267-73
pubmed: 25362482
Cancer Med. 2019 Nov;8(16):6986-6994
pubmed: 31588679
Oncologist. 2019 Jun;24(6):e327-e337
pubmed: 30796151
JAMA Oncol. 2016 Feb;2(2):234-40
pubmed: 26633184
Inflamm Bowel Dis. 2012 Jun;18(6):1164-76
pubmed: 21887729
J Clin Oncol. 2020 Jan 20;38(3):193-202
pubmed: 31790344
N Engl J Med. 2018 Jul 05;379(1):54-63
pubmed: 29972759
Clin Gastroenterol Hepatol. 2017 Aug;15(8):1207-1217.e4
pubmed: 28215616
J Immunol. 2009 Feb 15;182(4):2102-12
pubmed: 19201863
Ann Oncol. 2017 Feb 1;28(2):368-376
pubmed: 27687304
Clin Mol Hepatol. 2020 Jul;26(3):328-339
pubmed: 32460459
J Clin Oncol. 2008 Jun 20;26(18):2992-8
pubmed: 18565886
Lancet. 2018 Mar 24;391(10126):1163-1173
pubmed: 29433850
World J Gastroenterol. 2013 Nov 14;19(42):7327-40
pubmed: 24259964
Arthritis Rheumatol. 2019 Dec;71(12):2100-2111
pubmed: 31379105
Gastroenterology. 2015 Oct;149(5):1226-1239.e4
pubmed: 26099527
J Exp Med. 2000 Jul 17;192(2):295-302
pubmed: 10899916
Ann Intern Med. 2018 Jan 16;168(2):121-130
pubmed: 29297009
N Engl J Med. 2015 May 21;372(21):2006-17
pubmed: 25891304
Cancer Immunol Immunother. 2018 May;67(5):825-834
pubmed: 29487980
J Oncol. 2015;2015:847383
pubmed: 26060497
Clin Cancer Res. 2019 Feb 1;25(3):912-920
pubmed: 30274981
Clin Cancer Res. 2019 Jan 15;25(2):515-523
pubmed: 30348638
Lancet Oncol. 2020 Jun;21(6):808-820
pubmed: 32502443
Drugs. 2009;69(2):223-40
pubmed: 19228077
Cancer Immunol Immunother. 2018 Jul;67(7):1079-1090
pubmed: 29687231
N Engl J Med. 2020 May 14;382(20):1894-1905
pubmed: 32402160
PLoS One. 2020 Apr 2;15(4):e0231003
pubmed: 32240238
Lancet. 2017 Jan 7;389(10064):56-66
pubmed: 27932229
Mol Cancer. 2019 Nov 6;18(1):155
pubmed: 31690319
Front Immunol. 2017 Nov 15;8:1547
pubmed: 29230210
Front Oncol. 2014 Apr 02;4:70
pubmed: 24765614
Curr Opin Cell Biol. 1999 Apr;11(2):203-10
pubmed: 10209159
Radiology. 2015 Dec;277(3):903-12
pubmed: 26131911
N Engl J Med. 2017 Dec 21;377(25):2500-2501
pubmed: 29262275
J Exp Med. 1996 Aug 1;184(2):783-8
pubmed: 8760834
Future Oncol. 2019 Jun;15(16):1811-1822
pubmed: 30969136
Cancers (Basel). 2019 Dec 20;12(1):
pubmed: 31877664
J Biomed Sci. 2017 Apr 4;24(1):26
pubmed: 28376884
Clin Cancer Res. 2008 Sep 1;14(17):5459-65
pubmed: 18765537
N Engl J Med. 2011 Sep 22;365(12):1118-27
pubmed: 21992124
Antivir Chem Chemother. 2020 Jan-Dec;28:2040206620921331
pubmed: 32418480
Clin Gastroenterol Hepatol. 2020 Jun 19;:
pubmed: 32565289
J Clin Oncol. 2020 Feb 20;38(6):576-583
pubmed: 31800340
Lung Cancer. 2019 Sep;135:29-32
pubmed: 31446999
Liver Cancer. 2019 Jul;8(4):221-238
pubmed: 31602367
Gastroenterology. 2004 May;126(5):1347-57
pubmed: 15131796
Vasc Cell. 2014 Sep 06;6:18
pubmed: 25197551
J Hepatol. 2013 Jul;59(1):81-8
pubmed: 23466307
PLoS One. 2012;7(12):e49717
pubmed: 23284624
Nat Rev Clin Oncol. 2011 May;8(5):292-301
pubmed: 21386818